ACHP’s responds to Medicare’s proposal to sharply limit coverage of the controversial Alzheimer’s drug Aduhelm.
Following a White House announcement, ACHP responds to the lack of a coordinated national testing strategy and rapid at-home COVID test availability.
Besides being outrageously priced, Aduhelm is an unproven, potentially dangerous drug—a drug Medicare simply should not cover.
ACHP spoke with Sarah Kliff about the rushed testing implementation timeline following new rules requiring at-home COVID test coverage.
When choosing a Medicare Advantage (MA) plan, there are several factors to consider. Fortunately, a lot of information – including network, pricing, performance in treating certain conditions and quality ratings – is publicly available.
Medicare Advantage (MA) serves diverse populations. In fact, MA enrolls a higher percentage of people of color than traditional Medicare.
Today, the evidence is clear: Medicare Advantage is working, providing exceptional coverage and care for nearly 23 million seniors.
Medicare Advantage prioritizes quality over volume of care by encouraging more effective, coordinated and managed health care.
Following new COVID testing guidance, ACHP comments on the lack of a coordinated national testing strategy and at-home test availability.
ACHP responds to the Biden Administration requiring private insurers to provide coverage for rapid COVID-19 tests.
HealthLeaders recognizes ACHP and its members for innovation and recommendations on telehealth, drug pricing, health equity, access and more.